Sedative-Hypnotic Drugs

Correct Answer

B — Long-acting barbiturate

Rationale

Phenobarbital is classified as a long-acting barbiturate, with a half-life of 80 to 120 hours. This extended duration distinguishes it from the short-acting barbiturates used historically for sleep and from the ultra-short-acting agents such as thiopental used for anesthesia induction. Its long half-life makes phenobarbital suitable for chronic clinical applications including seizure management and provides a self-tapering effect that is exploited in alcohol withdrawal protocols.

Correct Answer

D — Serotonin 5-HT1A receptor partial agonist

Rationale

Buspirone is classified as a serotonin 5-HT1A receptor partial agonist. This receptor target distinguishes it from every other agent discussed in this chapter — it has no affinity for the gamma-aminobutyric acid type A receptor, melatonin receptors, or orexin receptors. Its serotonergic mechanism accounts for its anxiolytic effect in generalized anxiety disorder as well as its delayed onset of action, its lack of dependence potential, and its absence of cross-tolerance with benzodiazepines.

Correct Answer

A — N-methyl-D-aspartate receptor antagonism

Rationale

Ketamine is classified as an N-methyl-D-aspartate receptor antagonist. It blocks the N-methyl-D-aspartate glutamate receptor by entering and occluding the open channel pore, preventing calcium influx. This mechanism is distinct from all other intravenous sedative-hypnotics discussed in this module: propofol and etomidate are gamma-aminobutyric acid type A positive allosteric modulators, and dexmedetomidine is an alpha-2 adrenergic receptor agonist. Ketamine has no significant mu-opioid receptor activity.

Correct Answer

C — Alpha-2 adrenergic receptor

Rationale

Dexmedetomidine is classified as a highly selective alpha-2 adrenergic receptor agonist. This receptor selectivity places it in a pharmacological class entirely distinct from the other intravenous sedatives in this module — it does not act at gamma-aminobutyric acid type A receptors, N-methyl-D-aspartate receptors, or opioid receptors. Alpha-1 agonism produces vasoconstriction; beta-1 agonism increases heart rate and contractility; beta-2 agonism causes bronchodilation — none of these describe dexmedetomidine's primary receptor classification.

Correct Answer

B — Gamma-aminobutyric acid type A receptor positive allosteric modulator

Rationale

Etomidate is classified as a gamma-aminobutyric acid type A receptor positive allosteric modulator. It shares this receptor mechanism with propofol and with barbiturates, but it is structurally an imidazole derivative — not a barbiturate. This distinction matters because etomidate's receptor classification does not predict its most clinically significant property, which is exceptional hemodynamic stability, or its most important adverse effect, adrenocortical suppression via 11-beta-hydroxylase inhibition. N-methyl-D-aspartate antagonism is the mechanism of ketamine; alpha-2 agonism is the mechanism of dexmedetomidine.

Correct Answer

D — Ultra-short-acting barbiturate

Rationale

Thiopental is classified as an ultra-short-acting barbiturate. Its extremely rapid onset and brief clinical effect result from its high lipophilicity — it crosses the blood-brain barrier within one arm-to-brain circulation time but rapidly redistributes from the brain to peripheral tissues, terminating its central nervous system effect. This pharmacokinetic profile made it the standard intravenous induction agent for decades before propofol largely replaced it. Phenobarbital, by contrast, is the prototype long-acting barbiturate with a half-life of 80 to 120 hours.

Correct Answer

A — Barbiturates increase the duration of chloride channel opening; benzodiazepines increase the frequency of chloride channel opening

Rationale

Barbiturates and benzodiazepines both enhance gamma-aminobutyric acid type A receptor-mediated chloride influx, but through different gating mechanisms. Barbiturates bind within or near the chloride channel pore and increase the duration of each opening event. Benzodiazepines bind at a distinct allosteric site and increase the frequency with which the channel opens in response to gamma-aminobutyric acid. Both effects require gamma-aminobutyric acid to be present at therapeutic concentrations, though this requirement is lost for barbiturates at supratherapeutic doses.

Correct Answer

C — At supratherapeutic concentrations, barbiturates directly activate gamma-aminobutyric acid type A chloride channels without requiring gamma-aminobutyric acid, producing uncapped central nervous system depression

Rationale

The critical pharmacological distinction explaining barbiturate lethality in overdose is their ability to directly activate the gamma-aminobutyric acid type A receptor chloride channel at supratherapeutic concentrations, bypassing the requirement for endogenous gamma-aminobutyric acid. Benzodiazepines can only enhance the receptor's response to gamma-aminobutyric acid and therefore have a ceiling on their central nervous system depressant effect. Barbiturates have no such ceiling — escalating doses produce escalating degrees of central nervous system depression through direct channel activation, culminating in respiratory arrest. Barbiturate binding is reversible, and the key mechanism is direct channel activation rather than N-methyl-D-aspartate receptor blockade or prolonged half-life alone.

Correct Answer

D — Phenobarbital induces cytochrome P450 enzymes, accelerating warfarin metabolism and reducing anticoagulation

Rationale

Phenobarbital is one of the most potent inducers of hepatic cytochrome P450 enzymes in clinical use, upregulating cytochrome P450 1A2, 2C9, 2C19, and 3A4 as well as P-glycoprotein. Warfarin is metabolized primarily by cytochrome P450 2C9 and 3A4; induction of these enzymes accelerates warfarin clearance, reducing plasma warfarin levels and decreasing anticoagulant effect. This interaction requires close monitoring of the international normalized ratio when phenobarbital is started, adjusted, or stopped in a patient receiving warfarin. Phenobarbital is an inducer, not an inhibitor, of cytochrome P450 enzymes, and its interaction with warfarin is metabolic rather than through protein binding displacement or intestinal absorption blockade.

Correct Answer

B — Buspirone requires one to four weeks to produce anxiolytic effects and has no gamma-aminobutyric acid type A receptor activity, providing no cross-tolerance with benzodiazepines

Rationale

Buspirone acts via serotonin 5-HT1A receptor partial agonism, a mechanism that requires sustained receptor adaptation to produce anxiolysis — onset takes one to four weeks. It has no gamma-aminobutyric acid type A receptor activity and therefore provides no cross-tolerance with benzodiazepines. Benzodiazepine withdrawal is driven by gamma-aminobutyric acid type A receptor downregulation, and only agents that engage this receptor system can substitute during a taper. Buspirone cannot fill this role. It is not rapidly metabolized before reaching the brain, does not block serotonin reuptake, and is not a controlled substance.

Correct Answer

A — Impaired mitochondrial fatty acid oxidation, leading to energy failure in cardiac and skeletal muscle

Rationale

Propofol infusion syndrome is caused by impaired mitochondrial fatty acid oxidation — the pathway by which cardiac and skeletal muscle generate energy under metabolic stress. When this pathway is disrupted by prolonged high-dose propofol infusion, cells cannot maintain adequate adenosine triphosphate production, producing severe metabolic acidosis, rhabdomyolysis, hyperkalemia, and potentially fatal cardiac arrhythmias. The syndrome typically occurs with infusions exceeding 48 hours at doses above 5 milligrams per kilogram per hour. While the lipid emulsion formulation of propofol can raise triglyceride levels, this is a separate consideration and is not the mechanism of propofol infusion syndrome itself.

Correct Answer

C — Dexmedetomidine activates alpha-2 receptors in the locus coeruleus, reducing norepinephrine-mediated arousal signaling in a manner that mimics natural sleep rather than pharmacological sedation

Rationale

Dexmedetomidine acts at alpha-2 adrenergic receptors in the locus coeruleus, the principal noradrenergic nucleus governing cortical arousal. By inhibiting norepinephrine release from locus coeruleus neurons, it reduces the ascending arousal signaling that maintains wakefulness. This pathway resembles the neurological state of natural sleep, explaining why patients under dexmedetomidine sedation can be awakened by stimulation and return to a cooperative state — unlike patients sedated with gamma-aminobutyric acid type A-active agents. Because the primary mechanism does not involve direct brainstem respiratory center depression, dexmedetomidine produces substantially less respiratory compromise than propofol, benzodiazepines, or opioids at sedating doses.

Correct Answer

D — Ketamine inhibits neuronal catecholamine reuptake, increasing sympathetic tone and supporting heart rate, blood pressure, and cardiac output

Rationale

Ketamine's sympathomimetic hemodynamic profile is the pharmacological basis for its preference in hemodynamically compromised patients. By inhibiting reuptake of epinephrine and norepinephrine at neuronal synapses, ketamine increases circulating catecholamine activity, producing increases in heart rate, blood pressure, and cardiac output. In a patient with hemorrhagic shock or other causes of hemodynamic compromise, these effects support perfusion during the vulnerable period of induction and intubation. Propofol, by contrast, decreases systemic vascular resistance through gamma-aminobutyric acid type A modulation and produces hypotension — a potentially lethal effect in an already compromised patient. Ketamine's respiratory and duration properties are secondary considerations; its hemodynamic advantage is the primary mechanism-based reason for its selection in shock states.

Correct Answer

B — Etomidate inhibits 11-beta-hydroxylase, the enzyme required for the final step of cortisol synthesis in the adrenal cortex

Rationale

Etomidate inhibits 11-beta-hydroxylase, the mitochondrial enzyme in the adrenal cortex responsible for converting 11-deoxycortisol to cortisol in the final biosynthetic step. Even a single induction dose can suppress cortisol production for 12 to 24 hours. With continuous infusion this suppression is prolonged, which is why continuous etomidate infusion for intensive care unit sedation has been abandoned. The adrenocortical suppression is a direct enzymatic effect on steroid biosynthesis — it is not mediated through pituitary adrenocorticotropic hormone suppression, peripheral receptor blockade, or cytochrome P450 induction in the adrenal cortex.

Correct Answer

C — At the doses used, phenobarbital can directly activate gamma-aminobutyric acid type A chloride channels without requiring gamma-aminobutyric acid, bypassing the receptor downregulation that limits benzodiazepine efficacy

Rationale

During sustained seizure activity, gamma-aminobutyric acid type A receptors undergo internalization and functional downregulation, progressively reducing the efficacy of benzodiazepines, which require gamma-aminobutyric acid to be present to enhance channel activity. Phenobarbital retains efficacy in this setting because at sufficient concentrations it can directly activate gamma-aminobutyric acid type A chloride channels without requiring gamma-aminobutyric acid — bypassing the receptor population that has become unresponsive to benzodiazepines. This direct activation property, absent in benzodiazepines, is the pharmacological rationale for phenobarbital as a recognized agent in refractory seizures. Phenobarbital's mechanism in this context is not through N-methyl-D-aspartate receptor blockade or adrenergic pathways.

Correct Answer

A — Impaired mitochondrial fatty acid oxidation caused by high-dose propofol infusion, leading to energy failure in cardiac and skeletal muscle

Rationale

This patient's presentation — metabolic acidosis, severe rhabdomyolysis, hyperkalemia, and new cardiac arrhythmia after more than 48 hours of high-dose propofol infusion — is the clinical picture of propofol infusion syndrome. The mechanism is impaired mitochondrial fatty acid oxidation: propofol disrupts the ability of cardiac and skeletal muscle cells to use fatty acids as an energy source, leading to cellular energy failure, lactic acidosis, and muscle breakdown. Risk factors in this patient include high dose (above 5 milligrams per kilogram per hour), duration exceeding 48 hours, traumatic brain injury, and critical illness. The lipid emulsion vehicle can raise triglycerides but does not cause this syndrome; the mechanism is mitochondrial rather than nephrotoxic or receptor-mediated.

Correct Answer

D — Ketamine inhibits neuronal catecholamine reuptake, increasing sympathetic tone and supporting blood pressure and cardiac output, whereas propofol decreases vascular resistance and worsens hypotension

Rationale

Ketamine is selected in hemodynamically unstable patients because of its sympathomimetic mechanism: by inhibiting reuptake of epinephrine and norepinephrine at neuronal synapses, it increases catecholamine activity, raising heart rate, blood pressure, and cardiac output. This hemodynamic profile is the opposite of propofol, which decreases systemic vascular resistance through gamma-aminobutyric acid type A modulation and routinely produces clinically meaningful hypotension. In a patient already in hemorrhagic shock, propofol-induced vasodilation could be fatal, whereas ketamine's sympathomimetic effects support perfusion pressure during the vulnerable induction period. Ketamine does produce less respiratory depression and maintains airway reflexes better than propofol, but the primary mechanism-based rationale for selection in shock is hemodynamic, not respiratory.

Correct Answer

B — Etomidate inhibited 11-beta-hydroxylase in the adrenal cortex, blocking the final enzymatic step in cortisol biosynthesis

Rationale

Etomidate inhibits 11-beta-hydroxylase, the mitochondrial enzyme in the adrenal cortex responsible for converting 11-deoxycortisol to cortisol in the final biosynthetic step. Even a single induction dose produces measurable adrenocortical suppression lasting 12 to 24 hours. In a patient with septic shock — a state that already stresses adrenal reserve — this transient suppression can be clinically significant, contributing to refractory hypotension despite adequate vasopressors. The failed corticotropin stimulation test confirms the problem is at the adrenal level, not at the pituitary. Etomidate does not suppress adrenocorticotropic hormone release, does not induce cytochrome P450 enzymes in the adrenal gland, and does not block glucocorticoid receptors in peripheral tissues.